December 13, 2021 11:06 AM EST
News Briefing

In­tel­lia dos­es first pa­tient with an­ti-HAE gene ther­a­py; So­bi an­nounces new R&D chief

Paul Schloesser

Associate Editor

Gene ther­a­py biotech In­tel­lia Ther­a­peu­tics has dosed its first pa­tient with genome edit­ing can­di­date NT­LA-2002, its drug can­di­date for hered­i­tary an­gioede­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times